Chun-Nan Chen, Ph.D., is Chief Executive Officer and Chief Scientific Officer of SCT.
Dr. Chen is a research scientist and business manager with twenty years of experience. He has published in peer-reviewed journals, lectured internationally, and is well respected for the quality and integrity of his research.
At Applied Biosystems in charge of human genome mapping, he had extensive collaboration with senior research labs worldwide, and was in charge of personnel, budgeting, planning, scheduling, operations and quality control. Dr. Chen was a visiting scholar at Yang Ming University, a member of Taiwan’s National Science Council on Biotechnology, and an adviser for the Executive Yuan. He was also an invited speaker at numerous scientific meetings both in Taiwan and the United States, taught the Advanced Genome Sequence Analysis course at Cold Spring Harbor Laboratory.
Dr. Chen received his postdoctoral training in Biochemistry Molecular Biology from UC San Francisco, his Ph.D. from Michigan State University, and his B.S. from National Taiwan University, and held senior scientific positions at Celera Genomics, Applied Biosystems, Pharmageneis, SyStemix and DesignRx Pharmaceuticals. Dr. Chen is a registered United States Patent Agent.
Jim Bowlby is Chief Operations Officer of SCT.
Jim Bowlby is a very experienced mathematician and physicist, who is a repeat entrepreneur and has over thirty years of practical business and scientific experience.
At Applied Biosystems, he ran the Bioinformatics and Algorithm group which was responsible for improving the DNA base calling, using a wide variety of advanced mathematics. At Woodside Technology, he developed an array-based DNA amplification system. At Vita Genomics, he experimented with advanced haplotyping techniques to mine the Celera database for disease genes prevalent in Asian populations. Mr. Bowlby was previously CTO of Anagene Corporation.
Mr. Bowlby has an A.B. in mathematics and a M.A. in physics from the University of California, Berkeley, and studied under Nobel Laureates Owen Chamberlain and E. O. Lawrence and Panofsky Prize winner David Nygren at Lawrence Berkeley Labs. Mr. Bowlby was a founder of several Silicon Valley startups. Early in his career he was a Phi Beta Kappa undergraduate student at the University of California, Berkeley, and received the UC Physics Departmental Citation.
Rich Jorgensen is an experienced corporate business manager and engineer, with over 30 years in several prominent silicon valley high tech companies. He has held executive positions in companies ranging from data storage and peripherals, broadcasting products, and preventing internet downloading and piracy.
Mr. Jorgensen has been on corporate patent committees and contributed to filings related to data encoding and encryption. He also has consulted on several Military projects regarding storage and data integrity. Mr. Jorgensen is a past board member of the Computer History Museum in Mountain View, CA Mr. Jorgensen obtained his Engineering Degree from the University of California at Berkeley, his MBA from Santa Clara University, and additional Executive Education from the Wharton School of Business at the University of Pennsylvania.
Mr. Tufts has extensive experience in general corporate representation, with a particular emphasis on start-up and emerging businesses and financings, mergers and acquisitions and corporate taxation. Prior to founding Tufts, Stephenson & Kasper LLP in 1999, Mr. Tufts was a name partner at the law firm of Jackson Tufts Cole & Black, LLP. Mr. Tufts is a current or prior Director and/or Officer of various corporations, including Adia Services, Inc., American Microsystems, Inc., Autodesk, Inc., Cardinal Sound Labs, Inc., Holex Incorporated, IntelliGeneScan, Inc., Materials Analysis, Inc., NovaBay Pharmaceuticals, Inc., OSI Security Devices, Inc., Pacific Genuity, Inc., Pacific Measurements, Inc., Planet Biotechnology, Inc., PLC Diagnostics, Inc., Prometrix Corporation, Sensys Instruments Corporation, Tamal Energy, Inc., and Z-Plane, Inc.
Mr. Tufts is a certified tax specialist (corporate taxation) under the State Bar of California Board of Legal Specialization. In addition to his commercial practice, Mr. Tufts has extensive non-profit and volunteer experience, such as:
- Governor, Executive Committee Member and Secretary, San Francisco Symphony
- Council Member, The Friends of the Bancroft Library
- Chair, San Francisco Bay Conservation and Development Commission (and Chair, Seaport Planning Advisory Committee)
- Chair, Port of San Francisco Waterfront Plan Citizens Advisory Committee
- Vice President and Member, Board of Directors, Olympic Club
- Member, Board of Directors, Seadrift Association Homeowners
- Member, Board of Trustees, San Francisco Art Institute
Dr. Najafi is the founder, Chairman, and CEO of NovaBay Pharmaceuticals, Inc, a publicly traded pharmaceutical company. He has served as President since July 2002, and as Chief Executive Officer since November 2004. Previously, Dr. Najafi served in various management positions within NovaBay including as Chief Scientific Officer.
Prior to founding NovaBay, Dr. Najafi was the President and CEO of California Pacific Labs, Inc., a chemical laboratory safety devices company. He worked for Perkin Elmer Applied Biosystems, where he was responsible for the synthesis of DNA components and where he was recognized as “Perkin Elmer Scientist of the Year”. He has also worked for Aventis (then Rhone Poulenc Rorer) synthesizing a new generation of asthma drugs, and for Aldrich Chemical Co. as team leader in Organo-Silicon development.
Dr. Najafi has a Ph.D. in Chemistry from the University of California at Davis and a B.S. and M.S. in Chemistry from the University of San Francisco. He has written numerous articles in peer-reviewed journals and has been an inventor on several US patents.
Dr. Yen-Ming Hsu is the CEO of AB Biosciences, Inc. at Boston, Massachusetts.
Prior to co-founding AB Biosciences, Dr. Hsu headed a protein engineering group in the Research Department of Biogen-Idec, Cambridge, Massachusetts, where he spent over two decades in developing a dozen therapeutic antibodies for immunological and oncological indications. Prior to joining Biogen-Idec (then Biogen), Dr. Hsu was a post-doctoral fellow in Professor Guido Guidotti’s lab at the Cellular and Molecular Biochemistry, Harvard, where he discovered the 2nd isoform of the Na+-K+ ATPase in the axolemma of rat brain stem. Dr. Hsu obtained his Ph.D. in Biochemistry at John L. Wang’s, Michigan State University, where he studied the density-dependent growth of monolayer cell cultures.
As an accomplished biochemist, Dr. Hsu has designed over a hundred recombinant soluble ligand and receptor proteins from their membrane anchored counterparts as part of his toolkit for developing therapeutic biologics targeting these surface molecules. His research area focuses on proteins of TNF receptor and ligand super-families, costimulatory/checkpoint proteins as well as CD molecules of adaptive and innate immunity. His biologics developmental efforts focus on antibody molecules and their derivatives. Dr. Hsu’s in-depth knowledge and hands-on experience in the structures and functions of immunoglobulin molecules are invaluable for the development of antibody drugs. He has 43 peer-reviewed publications and 27 granted patents.